WINNIPEG, September 11, 2025 — TheNewswire - Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced that two patients have been selected as candidates eligible to receive Cytophage’s proprietary new bacteriophage (phage) product targeting Staphylococcus aureus, a common cause of chronic prosthetic joint infection (PJI). This marks another critical milestone in the Company’s ongoing efforts to advance phage-based solutions for treatment-resistant infections in humans. 

 

Cytophage is leveraging its unique technology and extensive infectious diseases experience to optimize a phage designed to combat Staphylococcus aureus - a key target bacterium for the Company’s multi-phage PJI treatment currently in development. This builds upon Cytophage’s previous clinical achievements, including the delivery of Canada’s first bacteriophage therapy to a patient with a PJI in 2024, and demonstrates the Company’s ongoing success in creating innovative therapies to save and/or enhance patient lives. 

 

“Every new patient treated with one of our phage therapies brings us one step closer to developing our multi-bacterial PJI treatment,” said Dr. Steven Theriault, CEO of Cytophage. “Identifying these new candidates underscores the real-world impact that our innovative approach is making and reinforces our commitment to delivering effective solutions for treatment-resistant infections.”

 

Today’s announcement supports Cytophage’s broader goal of developing multi-phage “cocktails” designed to address a wide range of bacterial pathogens responsible for PJIs, including both staphylococci and enterococci. Results from patient treatments will directly inform the ongoing development and optimization of these phage cocktails, ultimately aiming to maximize impact. 

 

Next Steps

Cytophage is currently working closely with its hospital partners to secure the necessary ethics and regulatory approvals, including those from Health Canada (Open Label Individual Patient trial) and Environment Canada (New Substance Notification). The Company expects to proceed with this treatment in Q4 of 2025. Physician follow-up will continue throughout 2026.  

Cytophage has targeted PJIs given their severe consequences for patients and the significant economic impact on the healthcare system. According to the Canadian Institute for Health Information (CIHI), over 130,000 hip and knee replacements are performed annually in Canada that have the potential to become chronically infected. A review in the New England Journal of Medicine reported the lifetime cost of such an infection in the hip can cost over $390,000 USD ($540,000 CAD) in treatment and hospitalization. Cytophage aims to develop precision phage products to address these high-costs and most importantly, alleviate patient suffering.

 

About Cytophage 
Cytophage Technologies (TSXV:CYTO / FSE: 70G) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. 

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences.

Cytophage is improving bacteria’s natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast-track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR). The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 EU countries, US, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products. 

Cytophage is using a de-risked and patented technology to advance innovative and cost competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.  

For more information on Cytophage Technologies and its innovative work in bacteriophage therapy, please visit www.cytophage.com.

For further information please contact:  

Heather Medwick, Chief Operating Officer 
heather@cytophage.com | 431 388 8873 

Cytophage Investor Alerts: https://cytophage.com/subscribe/

  

Cautionary Statement on Forward-Looking Information 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.  

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.